Answers are grounded in this paper and cite their sources.
MK-7655 (1) is a β-lactamase inhibitor in clinical trials as a combination therapy for the treatment of bacterial infection resistant to β-lactam antibiotics. Its unusual structural challenges have inspired a rapid synthesis featuring an iridium-catalyzed N-H insertion and a series of late stage transformations designed around the reactivity of the labile bicyclo[3.2.1]urea at the core of the target.
No takes yet. Share an insight, caveat, or question.
Mangion et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: